Atossa Therapeutics, Inc.

NasdaqCM:ATOS Stock Report

Market Cap: US$49.1m

Atossa Therapeutics Valuation

Is ATOS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of ATOS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: Insufficient data to calculate ATOS's future cash flow value for valuation analysis.

Significantly Below Future Cash Flow Value: Insufficient data to calculate ATOS's future cash flow value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ATOS?

Key metric: As ATOS is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for ATOS. This is calculated by dividing ATOS's market cap by their current book value.
What is ATOS's PB Ratio?
PB Ratio1.2x
BookUS$39.35m
Market CapUS$49.08m

Price to Book Ratio vs Peers

How does ATOS's PB Ratio compare to its peers?

The above table shows the PB ratio for ATOS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average4.5x
XLO Xilio Therapeutics
1.3x-21.85%US$48.1m
PSTV Plus Therapeutics
10.3x57.79%US$45.3m
PDSB PDS Biotechnology
5.6x39.92%US$50.3m
DWTX Dogwood Therapeutics
0.6x32.39%US$46.1m
ATOS Atossa Therapeutics
1.2x58.29%US$49.1m

Price-To-Book vs Peers: ATOS is good value based on its Price-To-Book Ratio (1.2x) compared to the peer average (4.5x).

Historical Price to Book Ratio

Historical Price to Book Ratio compares a stock's price to the book value of it's equity over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Book Ratio vs Industry

How does ATOS's PB Ratio compare vs other companies in the US Biotechs Industry?

56 CompaniesPrice / BookEstimated GrowthMarket Cap
ENLV Enlivex
0.1x-147.76%US$210.91m
CNTN Canton Strategic Holdings
0.5xn/aUS$193.20m
FRMM Forum Markets
0.5x147.01%US$98.92m
MGX Metagenomi Therapeutics
0.4x-9.03%US$56.43m
ATOS 1.2xIndustry Avg. 2.4xNo. of Companies83PB0246810+
56 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: ATOS is good value based on its Price-To-Book Ratio (1.2x) compared to the US Biotechs industry average (2.4x).

Price to Book Ratio vs Fair Ratio

What is ATOS's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ATOS PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio1.2x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate ATOS's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ATOS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$5.45
US$23.00
+322.02%
9.39%US$25.00US$20.00n/a3
Apr ’27US$5.11
US$43.75
+756.16%
101.38%US$120.00US$10.00n/a4
Mar ’27US$4.43
US$68.75
+1,451.92%
65.93%US$120.00US$10.00n/a4
Feb ’27US$8.47
US$86.25
+917.70%
31.05%US$120.00US$60.00n/a4
Jan ’27US$8.85
US$86.25
+874.58%
31.05%US$120.00US$60.00n/a4
Dec ’26US$11.13
US$85.31
+666.51%
30.03%US$116.25US$60.00n/a4
Nov ’26US$13.34
US$85.31
+539.33%
30.03%US$116.25US$60.00n/a4
Oct ’26US$13.74
US$85.31
+520.77%
30.03%US$116.25US$60.00n/a4
Sep ’26US$11.44
US$84.37
+637.32%
29.06%US$112.50US$60.00n/a4
Aug ’26US$12.34
US$84.37
+583.48%
29.06%US$112.50US$60.00n/a4
Jul ’26US$12.36
US$84.37
+582.48%
29.06%US$112.50US$60.00n/a4
Jun ’26US$11.66
US$91.25
+682.83%
24.27%US$108.75US$60.00n/a3
May ’26US$12.64
US$91.25
+621.63%
24.27%US$108.75US$60.00n/a3
Apr ’26US$9.76
US$90.00
+821.66%
23.57%US$105.00US$60.00US$5.113
Mar ’26US$11.49
US$90.00
+683.60%
23.57%US$105.00US$60.00US$4.433
Feb ’26US$12.63
US$90.00
+612.67%
23.57%US$105.00US$60.00US$8.473
Jan ’26US$14.16
US$90.00
+535.53%
23.57%US$105.00US$60.00US$8.853
Dec ’25US$19.50
US$87.50
+348.72%
22.50%US$105.00US$60.00US$11.133
Nov ’25US$21.30
US$82.50
+287.32%
19.64%US$97.50US$60.00US$13.343
Oct ’25US$21.90
US$82.50
+276.71%
19.64%US$97.50US$60.00US$13.743
Sep ’25US$20.55
US$81.25
+295.38%
18.59%US$93.75US$60.00US$11.443
Aug ’25US$19.35
US$81.25
+319.90%
18.59%US$93.75US$60.00US$12.343
Jul ’25US$18.00
US$81.25
+351.39%
18.59%US$93.75US$60.00US$12.363
Jun ’25US$19.50
US$80.00
+310.26%
17.68%US$90.00US$60.00US$11.663
May ’25US$22.95
US$70.00
+205.01%
20.20%US$90.00US$60.00US$12.643
Apr ’25US$30.00
US$68.75
+129.17%
18.00%US$86.25US$60.00US$9.763
US$23
Fair Value
76.3% undervalued intrinsic discount
3
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/04/27 13:54
End of Day Share Price 2026/04/27 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Atossa Therapeutics, Inc. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Edward WooAscendiant Capital Markets LLC
Pooya HemamiEdison Investment Research
Emily BodnarH.C. Wainwright & Co.